Agenus Q3 net loss $64.5M; cash falls to $106.3M; BLA for botensilimab planned mid-2024

AGENUS INC

2023-Q3 EPS reported -$0.57 revenue$72,513,000

Net loss of $64.5M for Q3 2023, compared to $56.7M in Q3 2022; nine-month loss $208.9M.
Cash, equivalents, and short-term investments $106.3M at Sep 30, down 45% from $193.4M at Dec 31, 2022.
Total revenue Q3 $24.3M, up 7% YoY; driven by non-cash royalty revenue of $20.4M.
BLA submission for botensilimab/BAL in MSS CRC planned mid-2024; milestone payment from BMS partnership expected by end of 2023.
Pursuing non-dilutive financing: selling non-strategic assets and partial milestone/royalty sales, expected to close by H1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

AGENUS INC reported financial results for the third quarter 2023.

Period: the third quarter 2023
Result: reported results

Exact text from the filing

On November 7, 2023, Agenus Inc. announced its financial results for the quarter ended September 30, 2023.

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

AGENUS INC filing history →

Source: SEC EDGAR

accession 0001157523-23-001659

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.